These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28728163)

  • 21. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.
    Smithers BM; Thomson I
    Thorac Surg Clin; 2013 Nov; 23(4):509-23. PubMed ID: 24199701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Piro G; Giacopuzzi S; Bencivenga M; Carbone C; Verlato G; Frizziero M; Zanotto M; Mina MM; Merz V; Santoro R; Zanoni A; De Manzoni G; Tortora G; Melisi D
    Br J Cancer; 2015 Sep; 113(6):878-85. PubMed ID: 26291056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer.
    Shaikh T; Thomay A; Ruth K; Cohen SJ; Meyer JE
    J Surg Oncol; 2015 Nov; 112(6):629-33. PubMed ID: 26430952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
    Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
    Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
    Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma.
    Mori Y; Okumura T; Tsunoda S; Sakai Y; Shimada Y
    Oncology; 2006; 70(5):378-89. PubMed ID: 17179732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimodality Approach for Esophageal Malignancies.
    Watkins AA; Zerillo JA; Kent MS
    Surg Clin North Am; 2021 Jun; 101(3):453-465. PubMed ID: 34048765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
    Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
    Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
    Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
    Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
    Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.
    Ben-David K; Rossidis G; Zlotecki RA; Grobmyer SR; Cendan JC; Sarosi GA; Hochwald SN
    Ann Surg Oncol; 2011 Nov; 18(12):3324-9. PubMed ID: 21479689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.